Waters launches LC platform-neutral bioseparations system

By Staff Reporter

- Last updated on GMT

Related tags: High performance liquid chromatography

Image c/o Waters
Image c/o Waters
Waters Corporation says its latest bioseparations system can drive cost-savings through reduced solvent volumes and decreased run times.

Aimed at late stage development, QC, and routine analysis pharmaceutical customers, processing tools maker Waters has launched the latest system in its Acquity Arc bioseparation analytical range: the Acquity Arc Bio system.

The system is based on Water’s Arc Multi-flow path technology, which director of Product Marketing Chromatography Systems Eric Grumbach said enables ease of transfer.

“Arc Multi-flow path technology enables the system to have a selectable dwell volume that delivers compatibility of both HPLC and UHPLC methods, significantly simplifying method transfer,”​ he told this publication.

Also known as delay volume, dwell volume is the volume inherent of the system components that result on how quickly the product once mixed will travel to the head of the separation columns. It affects the mixing behaviour of the solvents and is handled differently by different types of liquid chromatography (LC) systems.

According to Grumbach, matching the dwell volume of two disparate systems can help successfully transfer methods from one system to another, something the Arc Multi-Flowpath technology allows automatically.

“As for simplifying method development, the Acquity Arc Bio System, when paired with modern 2.5 µm UHPLC [ultra high performance liquid chromatography] columns, enables methods to be developed 4 fold faster than traditional 5 µm HPLC [high-performance liquid chromatography] columns,”​ he added.

“The combined ability to transition from HPLC to UHPLC, reduce solvent volumes, and decrease run times will result in significant efficiency improvements and cost savings.”

Related news

Related products

show more

Seasonal Vaccine Manufacturing

Seasonal Vaccine Manufacturing

Baxter BioPharma Solutions | 10-Feb-2021 | Technical / White Paper

The production of seasonal vaccines, such as those for influenza, presents unique challenges to manufacturers due to the necessary time constraints resulting...

Consideration and Options for Prefilled Syringes

Consideration and Options for Prefilled Syringes

Baxter BioPharma Solutions | 10-Feb-2021 | Technical / White Paper

Convenience, product differentiation, and less waste are great reasons for developing a product in a prefilled syringe. Baxter’s whitepaper describes the...

Rapid Biosafety Testing Enables the Future of Manufacturing

Rapid Biosafety Testing Enables the Future of Manufacturing

Viral Safety for mAb: Prevent, Detect, Remove | 23-Nov-2020 | Technical / White Paper

This white paper explores the factors driving the evolution toward faster biosafety testing and describes rapid approaches for adventitious agent testing...

Related suppliers

Follow us

Products

View more

Webinars